The drug was approved | Weixinkang potassium aspartate injection (plastic bottle) was approved for marketing

Recently, Yangpu Jingtai Pharmaceutical, a wholly-owned subsidiary of Weixinkang, received the "Drug Registration Certificate" for potassium aspartate injection approved and issued by the State Drug Administration (drug approval number: National Drug Approval number H20243591). At present, the company has begun to prepare for the listing.

Potassium aspartate injection is an electrolyte supplement for hypokalemia caused by various causes. It can be used to supplement potassium in the presence of the following symptoms or conditions: when combined with antihypertensive diuretics, adrenocorticosteroids, cardiac glycosides, insulin, or certain antibiotics; Hypokalemic periodic quadriplegia; Hypokalemia in the context of heart disease; Severe vomiting, diarrhea, insufficient potassium intake or after surgery.

As of April 30, 2024, there were 4 approved manufacturers of potassium aspartate injection in China (including Inner Mongolia Baiyi Pharmaceutical and Yangpu Jingtai), of which 2 manufacturers passed the consistency evaluation (including Yangpu Jingtai). The approved potassium aspartate injection adopted advanced polypropylene ampoule packaging technology.

According to the relevant national policies and regulations, the "Drug registration Certificate" obtained by Weixinkang is regarded as passing the consistency evaluation.